Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases
[caption id="attachment_9277" align="alignnone" width="747"] Press Release[/caption]
- Collaboration to explore liver cell targets using Dicerna?s GalXC? technology with the potential to deliver a significant number of clinical candidates
- Each company to retain rights to co-develop and co-commercialise product candidates
- Dicerna to receive upfront payment of USD 175 million and equity investment of USD 50 million
- Dicerna is eligible to receive an additional USD 75 million over the first three years, plus up to USD 357.5 million per target in potential milestone payments, and royalties on product sales
- An upfront payment of USD 175 million.
- A USD 50 million equity investment in Dicerna at a premium.
- USD 25 million annually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets.
- Up to USD 357.5 million per target in development, regulatory and commercialisation milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens.